^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VTP-600

    i
    Other names: VTP-600, ChAdOx1-MAGEA3-NYESO/MVA-MAGEA3 vaccine, ChAdOx-MVA cancer vaccine, VTP600, VTP 600
    Associations

    News

    Trials
    Company:
    Barinthus Bio, Cancer Research UK, Ludwig Institute for Cancer Research
    Drug class:
    Immunostimulant, NY ESO 1 inhibitor, MAGE-A3 modulator
    Related drugs:
    Associations

    News

    Trials
    3years
    A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
    P1/2, N=86, Recruiting, Cancer Research UK | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    VTP-600
    3years
    A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
    P1/2, N=86, Not yet recruiting, Cancer Research UK | Initiation date: May 2021 --> Sep 2021
    Trial initiation date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    VTP-600
    over3years
    A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 (clinicaltrials.gov)
    P1/2, N=86, Not yet recruiting, Cancer Research UK
    New P1/2 trial • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • MAGEA3 (MAGE Family Member A3)
    |
    VTP-600